Anavex Receives FDA Clearance for Blarcamesine Trial in Fragile X Syndrome
Anavex Life Sciences received FDA clearance to begin a Phase 2a trial of blarcamesine for Fragile X syndrome. The planned trial will assess safety, tolerability and pharmacokinetics in approximately 60 adult males. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelli